Supplementary Figure 1: Timeline of the study highlighting the screening period, the index period and the follow-up period.

**Screening period:** All patients were identified in NHIF database, who had a prescription of DPP4i or SGLT2i treatment from 1st of January 2009 till 31st of July 2019.

**Index period:** DPP4i or SGLT2i therapy started between 1st of August 2014 and 1st of July 2017 without any of these treatments 12 months before the index date. The index date was defined as the first day of any (either SGLT2i or DPP4i) treatments examined. When numerous index dates were identified for a patient, that case was excluded from the study to prevent immortal bias effect. **Follow-up period:** It started from 1st of August 2014 and closed on 31st of July 2019. Patients were followed from index date till the date of investigated event, the date of death or the end of study. Patients were censored if there was no prescription of investigated therapy for at least 90 days after the last prescription, or had any dispersion of drug from the counterpart arm.